Literature DB >> 32422630

Vaccine Potential of Mycobacterial Antigens against Asthma.

Abu Salim Mustafa1.   

Abstract

Asthma is a cause of substantial burden of disease in the world, including both premature deaths and reduced quality of life. A leading hypothesis to explain the worldwide increase of asthma is the "hygiene hypothesis," which suggests that the increase in the prevalence of asthma is due to the reduction in exposure to infections/microbial antigens. In allergic asthma, the most common type of asthma, antigen-specific T helper (Th)2 and Th17 cells and their cytokines are primary mediators of the pathological consequences. In contrast, Th1 and T regulatory (Treg) cells and their cytokines play a protective role. This article aims to review the information on the effect of mycobacteria and their antigens in modulating Th2/Th17 responses towards Th1/Treg responses and protection against asthma in humans and animal models.
© 2020 The Author(s) Published by S. Karger AG, Basel.

Entities:  

Keywords:  Asthma; Mycobacteria; Mycobacterial antigens

Mesh:

Substances:

Year:  2020        PMID: 32422630      PMCID: PMC7511680          DOI: 10.1159/000508719

Source DB:  PubMed          Journal:  Med Princ Pract        ISSN: 1011-7571            Impact factor:   1.927


  79 in total

1.  Immunomodulatory Effects of Adjuvants CPG, MPLA, and BCG on the Derp2-Induced Acute Asthma at Early Life in an Animal Model of BALB/c Mice.

Authors:  V Mohammadi-Shahrokhi; A Rezaei; A Andalib; A Rahnama; A Jafarzadeh; N Eskandari
Journal:  Inflammation       Date:  2017-02       Impact factor: 4.092

2.  Identification, diagnostic potential, and natural expression of immunodominant seroreactive peptides encoded by five Mycobacterium tuberculosis-specific genomic regions.

Authors:  Noora Y Al-Khodari; Rajaa Al-Attiyah; Abu S Mustafa
Journal:  Clin Vaccine Immunol       Date:  2010-12-22

3.  Effect of inhaled inactivated Mycobacterium phlei in children with moderate asthma.

Authors:  Moyu Ming; Chaoqian Li; Zhixi Luo; Shengqiu Lv
Journal:  Immunotherapy       Date:  2013-02       Impact factor: 4.196

Review 4.  The allergic asthma phenotype.

Authors:  Michael Schatz; Lanny Rosenwasser
Journal:  J Allergy Clin Immunol Pract       Date:  2014-11-06

5.  Development of spontaneous airway changes consistent with human asthma in mice lacking T-bet.

Authors:  Susetta Finotto; Markus F Neurath; Jonathan N Glickman; Shixin Qin; Hans A Lehr; Francis H Y Green; Kate Ackerman; Kathleen Haley; Peter R Galle; Susanne J Szabo; Jeffrey M Drazen; George T De Sanctis; Laurie H Glimcher
Journal:  Science       Date:  2002-01-11       Impact factor: 47.728

6.  Cytokines in response to proteins predicted in genomic regions of difference of Mycobacterium tuberculosis.

Authors:  Abu Salim Mustafa; Fatmah Al-Saidi; Abdel Salam Mahmoud El-Shamy; Rajaa Al-Attiyah
Journal:  Microbiol Immunol       Date:  2011-04       Impact factor: 1.955

7.  Characterization of human cellular immune responses to novel Mycobacterium tuberculosis antigens encoded by genomic regions absent in Mycobacterium bovis BCG.

Authors:  R Al-Attiyah; A S Mustafa
Journal:  Infect Immun       Date:  2008-06-23       Impact factor: 3.441

8.  On the impact of masking and blocking hypotheses for measuring the efficacy of new tuberculosis vaccines.

Authors:  Sergio Arregui; Joaquín Sanz; Dessislava Marinova; Carlos Martín; Yamir Moreno
Journal:  PeerJ       Date:  2016-02-11       Impact factor: 2.984

9.  The effect of inhaled inactived Mycobacterium phlei as a treatment for asthma.

Authors:  Moyu Ming; Chaoqian Li; Zhixi Luo; Shengqiu Lv; Qixiang Sun
Journal:  Mol Med Rep       Date:  2016-12-29       Impact factor: 2.952

10.  Immunization with an adenovirus-vectored TB vaccine containing Ag85A-Mtb32 effectively alleviates allergic asthma.

Authors:  Yiling Zhang; Ying Feng; Liang Li; Xianmiao Ye; Jinlin Wang; Qian Wang; Pingchao Li; Na Li; Xuehua Zheng; Xiang Gao; Chufang Li; Feng Li; Baoqing Sun; Kefang Lai; Zhong Su; Nanshan Zhong; Ling Chen; Liqiang Feng
Journal:  J Mol Med (Berl)       Date:  2018-01-04       Impact factor: 4.599

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.